{
    "ticker": "HSDT",
    "name": "Hemispherx Biopharma, Inc.",
    "description": "Hemispherx Biopharma, Inc. is a biopharmaceutical company dedicated to the development of innovative therapeutic products for the treatment of chronic viral infections and certain types of cancer. Founded in 1983 and headquartered in Philadelphia, Pennsylvania, the company focuses on harnessing the power of the immune system to treat diseases that affect millions globally. Hemispherx is particularly known for its lead product, Ampligen, an experimental drug that acts as a potent immune modulator and has shown promise in treating conditions such as chronic fatigue syndrome (CFS) and other viral infections. The company\u2019s research and development efforts are aimed at addressing critical unmet medical needs, and it is actively pursuing clinical trials to advance its product candidates. In addition to Ampligen, Hemispherx is exploring other compounds and therapies that leverage the immune response, striving to innovate and improve treatment options in the biopharmaceutical field. Hemispherx also emphasizes the importance of regulatory compliance and collaboration with health authorities to ensure the safety and efficacy of its products. With a strong commitment to scientific research and patient care, Hemispherx Biopharma aims to make a significant impact on public health and contribute to the advancement of medicine.",
    "industry": [
        "Biopharmaceutical",
        "Healthcare"
    ],
    "headquarters": "Philadelphia, Pennsylvania, USA",
    "founded": "1983",
    "website": "http://www.hemispherx.net",
    "ceo": "Thomas K. Equels",
    "social_media": {
        "twitter": "https://twitter.com/hemispherx",
        "linkedin": "https://www.linkedin.com/company/hemispherx-biopharma"
    },
    "investor_relations": "http://www.hemispherx.net/investor-relations",
    "key_executives": [
        {
            "name": "Thomas K. Equels",
            "position": "CEO"
        },
        {
            "name": "Robert A. M. K. R. Decker",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutic Products",
            "products": [
                "Ampligen"
            ]
        }
    ],
    "seo": {
        "meta_title": "Hemispherx Biopharma, Inc. | Innovative Biopharmaceutical Solutions",
        "meta_description": "Explore Hemispherx Biopharma, Inc., a leader in biopharmaceutical innovation focused on chronic viral infections and immune therapies.",
        "keywords": [
            "Hemispherx",
            "Biopharmaceutical",
            "Chronic Fatigue Syndrome",
            "Ampligen",
            "Immune Modulator"
        ]
    },
    "faq": [
        {
            "question": "What does Hemispherx Biopharma specialize in?",
            "answer": "Hemispherx Biopharma specializes in developing therapeutic products for chronic viral infections and cancer."
        },
        {
            "question": "What is Ampligen?",
            "answer": "Ampligen is Hemispherx's lead product that acts as an immune modulator and is being investigated for various viral infections."
        },
        {
            "question": "Where is Hemispherx Biopharma located?",
            "answer": "Hemispherx Biopharma is headquartered in Philadelphia, Pennsylvania, USA."
        },
        {
            "question": "When was Hemispherx Biopharma founded?",
            "answer": "Hemispherx Biopharma was founded in 1983."
        }
    ],
    "competitors": [
        "PFE",
        "BMY",
        "AMGN",
        "GILD"
    ],
    "related_stocks": [
        "JNJ",
        "MRNA",
        "VRTX",
        "REGN"
    ]
}